New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
08:58 EDTGALT, ICPT, GILDSummer Street discusses potential products to treat NASH
Summer Street does not believe side effects will prevent Intercept Pharmaceuticals' (ICPT) obeticholic acid from being a commercial success for treating nonalcoholic steatohepatitis, or NASH. The firm is concerned Galectin's (GALT) product could be immunogenic, causing it to fail, but sees a chance for Gilead's simtuzumab being effective despite a lack of data being released.
News For ICPT;GALT;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:01 EDTGILDOptions Update; December 19, 2014
iPath S&P 500 VIX Short-Term Futures down 27c to 29.90. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX according to Track Data.
09:37 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL TSLA BBRY AMZN CELG GILD JCP AMAT FB
06:26 EDTICPTIntercept price target lowered to $475 from $693 at Citigroup
Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCAís cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.
05:31 EDTGILDGilead, ONO announce exclusive license agreement to develop ONO-4059
ONO PHARMACEUTICAL and Gilead Sciences announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONOís oral Brutonís tyrosine kinase, or BTK, inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations, or ASEAN, countries, where ONO retains development and commercialization rights. ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO has presented preliminary Phase 1 data showing clinical activity in chronic lymphocytic leukemia and non-Hodgkin lymphoma at several scientific conferences. ONO and Gilead plan to develop ONO-4059 for the treatment of B-cell malignancies and other diseases as a monotherapy and in combination with approved and investigational agents, including combinations with kinase inhibitors in Gileadís portfolio.
December 18, 2014
09:35 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL FB TSLA PBR RAD AMAT NFLX GILD KMI TWTR
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 17, 2014
09:41 EDTGILDActive equity options trading
Subscribe for More Information
December 16, 2014
16:00 EDTGILDOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
December 12, 2014
09:35 EDTGILDActive equity options trading
Subscribe for More Information
December 11, 2014
16:01 EDTGILDOptions Update; December 11, 2014
Subscribe for More Information
11:55 EDTGILDGilead shares look cheap, poised for growth, Barron's says
Subscribe for More Information
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:54 EDTGILDGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
December 10, 2014
15:59 EDTGILDGilead sued by SEPTA over price of Hep C drug Sovaldi, WSJ reports
Subscribe for More Information
December 9, 2014
09:38 EDTGILDActive equity options trading
Subscribe for More Information
08:38 EDTGILDGilead price target raised to $130 from $110 at Argus
Subscribe for More Information
December 8, 2014
16:00 EDTGILDOptions Update; December 8, 2014
Subscribe for More Information
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use